Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison

被引:8
|
作者
Ward, Zoe [1 ]
Mafirakureva, Nyashadzaishe [1 ]
Stone, Jack [1 ]
Keevans, Mary [2 ]
Betts-Symonds, Graham [2 ,3 ]
Crowley, Desmond [4 ]
McHugh, Tina [5 ]
Avramovic, Gordana [6 ]
Lambert, John S. [5 ,6 ]
Vickerman, Peter [1 ]
机构
[1] Univ Bristol, Bristol, Avon, England
[2] Irish Prison Serv, Dublin, Ireland
[3] Irish Red Cross, Dublin, Ireland
[4] Irish Coll Gen Practitioners, Dublin, Ireland
[5] Mater Misericordiae Univ Hosp, Dublin, Ireland
[6] Univ Coll Dublin, Sch Med, Dublin, Ireland
基金
美国国家卫生研究院;
关键词
Ireland; People who inject drugs; Cost-effectiveness; Prison; Hepatitis C virus; Direct acting antivirals; INJECT DRUGS; PUBLIC-HEALTH; INFECTION; PEOPLE; HCV; METAANALYSIS; PREVENTION; SOFOSBUVIR; MORTALITY; IMPACT;
D O I
10.1016/j.drugpo.2021.103394
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: In Irish prisons, there is a high proportion of people who inject drugs (PWID; 26%) and a high prevalence of HCV (16%), making prison a high priority setting for HCV testing and treatment. We evaluate the cost-effectiveness of a mass HCV screening intervention in Mountjoy Prison, Dublin, compared to the standard-of-care of intermittent screening on committal. Methods: Primary cost data was collected from the intervention using an overall provider perspective. Standard-of-care (SOC) costs were estimated through interview. All costs were inflated to 2020 Euros. An HCV transmission and disease progression model among incarcerated and community PWID and ex-injectors was calibrated to the Dublin HCV epidemic, allowing inclusion of population-level health benefits. The model used intervention data, suggesting 419 individuals were screened, 50 HCV infections diagnosed and 32 individuals initiated treatment, to project the resulting costs and health benefits (quality adjusted life years or QALYs) over 50 years with 5% discounting. The incremental cost effectiveness ratio (ICER), cost per QALY gained, was estimated for the screening intervention compared to the standard-of-care. Probabilistic sensitivity analyses (PSA) determined the probability that the intervention was cost-effective compared to a willingness-to-pay threshold of (sic)30,000/QALY as used in Ireland. The ICER for 1- or 3-yearly mass screening in all Dublin prisons was also calculated. Results: The total direct costs of the intervention (not including treatment drug costs) was (sic)82,392, with most costs being due to staff(43%) and overhead or management costs (38%). Despite having little epidemiological impact due to the small numbers treated, over 50 years the incremental cost of the intervention was (sic)36,592 and 3.8 QALYs were gained, giving a mean ICER of (sic)9,552/QALY. The majority (84%) of PSA runs were below the willingness-to-pay threshold. Yearly mass screening had an ICER of (sic)2,729/QALY compared to SOC and gave a higher net monetary benefit ((sic)7,393,382) than screening every 3 years ((sic)6,252,816). Conclusion: Prison mass screening could be a cost-effective initiative for increasing testing and treatment of HCV in Ireland.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Hepatitis C virus screening of people with severe mental illness: a cost-effectiveness analysis
    Girardin, Francois
    Painter, Chris
    Hearmon, Natalie
    Eddowes, Lucy
    Kaiser, Stefan
    Negro, Francesco
    Vernaz, Nathalie
    JOURNAL OF HEPATOLOGY, 2020, 73 : S818 - S819
  • [32] Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies
    Christian Krauth
    Siegbert Rossol
    Gustaf Ortsäter
    Achim Kautz
    Kathrin Krüger
    Babette Herder
    Jona Theodor Stahmeyer
    BMC Infectious Diseases, 19
  • [33] Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States
    Chaillon, Antoine
    Rand, Elizabeth B.
    Reau, Nancy
    Martin, Natasha K.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (11) : 1888 - 1895
  • [34] Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies
    Krauth, Christian
    Rossol, Siegbert
    Ortsaeter, Gustaf
    Kautz, Achim
    Krueger, Kathrin
    Herder, Babette
    Stahmeyer, Jona Theodor
    BMC INFECTIOUS DISEASES, 2019, 19 (01)
  • [35] EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENING-A SYSTEMATIC REVIEW
    Sroczynski, G.
    Esteban, E.
    Conrads-Frank, A.
    Schwarzer, R.
    Muehlberger, N.
    Wright, D. R.
    Zeuzem, S.
    Siebert, U.
    VALUE IN HEALTH, 2008, 11 (06) : A437 - A438
  • [36] Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates
    Jacobs, RJ
    Rosenthal, P
    Meyerhoff, AS
    VACCINE, 2004, 22 (9-10) : 1241 - 1248
  • [37] Assessing the cost-effectiveness of hepatitis C screening strategies in France
    Deuffic-Burban, Sylvie
    Huneau, Alexandre
    Verleene, Adeline
    Brouard, Cecile
    Pillonel, Josiane
    Le Strat, Yann
    Cossais, Sabrina
    Roudot-Thoraval, Francoise
    Canvas, Valerie
    Mathurin, Philippe
    Dhumeaux, Daniel
    Yazdanpanah, Yazdan
    JOURNAL OF HEPATOLOGY, 2018, 69 (04) : 785 - 792
  • [38] Risk factors and prevalence, hepatitis B virus and hepatitis C virus among prison inmates, Chennai, India, 2015
    Ramamoorthy, M.
    Venketeswaran, A.
    Seenivasan, P.
    Revathy, M.
    Manimaran, M.
    Chitra, S.
    Malarvizhi, M.
    Frederick, T.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 53 : 90 - 90
  • [39] Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening
    Susan JM Hahné
    Irene K Veldhuijzen
    Lucas Wiessing
    Tek-Ang Lim
    Mika Salminen
    Marita van de Laar
    BMC Infectious Diseases, 13
  • [40] Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening
    Hahne, Susan J. M.
    Veldhuijzen, Irene K.
    Wiessing, Lucas
    Lim, Tek-Ang
    Salminen, Mika
    van de Laar, Marita
    BMC INFECTIOUS DISEASES, 2013, 13